Repackaged sartan tablets also face recalls

By Maggie Lynch contact

- Last updated on GMT

(Image: Getty/Moussa81)
(Image: Getty/Moussa81)

Related tags: Sartan, losartan, valsartan, Recall, Hetero Labs, India, Camber Pharmaceuticals

Sartan recalls continue as Legacy Pharmaceutical Packaging recalls 40 lots of losartan tablets at the consumer level.

After Camber Pharmaceuticals​ issued its voluntary nationwide recall of losartan tablets, when trace amounts of the possible carcinogen N-Nitroso N-Methyl 4-aminobutyric acid (NMBA) were found in the active pharmaceutical ingredient (API), Legacy Pharmaceutical Packaging followed suit and recalled 40 lots of its repackaged losartan tablets.

Legacy Pharmaceutical Packaging also recalled three repackaged lots of losartan tablets, after Torrent Pharmaceuticals issued a nationwide recall.

The recalled losartan tablets from both Torrent and Camber were manufactured at Hetero Labs, a pharmaceutical company based in Hyderabad, India.

Sartan recall saga

NMBA is the latest impurity to be found in sartan products, and while Camber did not receive any reports of adverse events, it issued a recall on 87 lots of its losartan tablets.

Recalls of sartan products have been ongoing, as N-nitrosodiethylamine​ (NDEA), NMBA, and N-nitrosodimethylamine (NDMA) have all been identified in valsartan, losartan and other products containing the API​.

The European Medicines Agency (EMA) has drawn conclusions as to the cause of the impurities and is continuing to investigate the presence of NDMA and NDEA in medicines to find a way in which the contamination can be identified and avoided.

Through the investigation, the EMA identified other nitrosamines, including N-nitrosoethylisopropylamine (EIPNA), and N-nitrosodiisopropylamine (DIPNA), which could be formed during the synthesis of sartans with a tetrazole ring.

Note: Legacy Pharmaceutical Packaging is an unrelated company to Legacy Pharmaceuticals.

Related news

Show more

Related products

show more

Multiple Sclerosis Analytical Report

Multiple Sclerosis Analytical Report

PatSnap | 15-Jun-2022 | Technical / White Paper

More than 2.3 million people are living with MS worldwide. Although there is no cure, new research and innovative treatments are continuously emerging....

Eastern & Western Manufacturing Solutions

Eastern & Western Manufacturing Solutions

Piramal Pharma Solutions | 15-Mar-2022 | Technical / White Paper

The best manufacturing site for a product can change throughout the life cycle. When bringing new drugs to market, biopharma companies may benefit from...

Related suppliers

Follow us


View more